Heart drug shows promise in preventing post-surgery rhythm disorder

NCT ID NCT04607122

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a low-dose infusion of landiolol, a short-acting beta-blocker, could prevent atrial fibrillation in 400 non-Asian patients after cardiac surgery. Participants received either landiolol or a placebo for up to 48 hours after surgery. The goal was to see if landiolol reduces the occurrence of this common and serious complication without causing more side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Landiolol (a short-acting beta-blocker)
What this could lead to
If it works, this could provide a safe way to prevent a common heart rhythm problem after heart surgery, reducing hospital stays and complications.
What could go wrong
This is a phase 3 trial, but previous positive results were in Japanese patients only. It may not work as well in non-Asian populations, and side effects like low blood pressure or slow heart rate are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CMC Ambroise Paré

    Neuilly-sur-Seine, 92200, France

  • Centre Cardiologique du Nord

    Saint-Denis, 93200, France

  • Hôpital Privé Jacques Cartier

    Massy, 91300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.